Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs.

about

Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs.

Item

http://www.wikidata.org/entity/Q38687974

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs.

@en

type

Item

label

Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs.

@en

prefLabel

Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs.

@en

P1476

Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs.

@en

P2093

Beat Schaer

http://www.w3.org/2001/XMLSchema#string

Christoph R Meier

http://www.w3.org/2001/XMLSchema#string

Ipek Celikyurt

http://www.w3.org/2001/XMLSchema#string

P2860

Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism

Safety of new oral anticoagulant drugs: a perspective

The Complex Role of Anticoagulation in Cirrhosis: An Updated Review of Where We Are and Where We Are Going

New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events

Dabigatran versus warfarin in patients with atrial fibrillation

Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor

A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement

Edoxaban: an update on the new oral direct factor Xa inhibitor.

Antiarrhythmic drugs: from mechanisms to clinical practice.

Antiarrhythmic agents: drug interactions of clinical significance.

P2888

s40264-017-0567-5

P304

1091-1098

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40264-017-0567-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michael Kühne

P577

2017-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1090387784

http://www.w3.org/2001/XMLSchema#string

P698

28689334

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation